Relapse of Dermatomyositis as a Marker of Occult Malignancy: Current Evidence and Clinical Implications.
DOI:
https://doi.org/10.12775/QS.2026.66.74455Keywords
dermatomyositis, malignancy, cancer-associated dermatomyositis, occult cancer, anti-TIF1γ antibodies, relapseAbstract
Background. Dermatomyositis (DM) is an inflammatory myopathy strongly associated with malignancy. Although cancer screening at disease onset is well established, the significance of disease relapse as a marker of occult malignancy remains uncertain.
Aim. To summarize current evidence on the relationship between dermatomyositis relapse and malignancy, focusing on epidemiology, serological risk stratification, pathophysiological mechanisms, and cancer-screening strategies.
Material and methods. A narrative review of studies, systematic reviews, meta-analyses, and international guidelines published between 2001 and 2026 was conducted using PubMed, Scopus, and Web of Science databases.
Results. Malignancy risk is highest during the first years after DM onset and is particularly increased in patients with anti-TIF1γ and anti-NXP2 antibodies. Emerging evidence suggests that disease relapse, progressive weakness, and treatment refractoriness may precede occult malignancy or indicate cancer recurrence. Current recommendations support risk-adapted screening based on clinical, demographic, and serological factors.
Conclusions. Relapse of dermatomyositis should prompt renewed evaluation for underlying malignancy, particularly in high-risk patients. Individualized screening strategies and autoantibody profiling remain essential for the early detection of cancer-associated disease.
References
1. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362(9388):971-982. doi:10.1016/S0140-6736(03)14368-1
2. Lundberg IE, Fujimoto M, Vencovsky J, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7(1):86. Published 2021 Dec 2. doi:10.1038/s41572-021-00321-x
3. Chen YJ, Wu CY, Huang YL, Wang CB, Shen JL, Chang YT. Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther. 2010;12(2):R70. doi:10.1186/ar2987
4. Yang Z, Lin F, Qin B, Liang Y, Zhong R. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol. 2015;42(2):282-291. doi:10.3899/jrheum.140566
5. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357(9250):96-100. doi:10.1016/S0140-6736(00)03540-6
6. Fiorentino DF, Chung LS, Christopher-Stine L, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum. 2013;65(11):2954-2962. doi:10.1002/art.38093
7. Yang H, Peng Q, Yin L, et al. Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res Ther. 2017;19(1):259. Published 2017 Nov 25. doi:10.1186/s13075-017-1469-8
8. Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med. 2016;280(1):8-23. doi:10.1111/joim.12451
9. Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: A clinicohistopathologic study. Neurology. 2016;87(3):299-308. doi:10.1212/WNL.0000000000002863
10. Bodoki L, Nagy-Vincze M, Griger Z, Betteridge Z, Szöllősi L, Dankó K. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun Rev. 2014;13(12):1211-1219. doi:10.1016/j.autrev.2014.08.011
11. Kilinc OC, Ugurlu S. Clinical features of dermatomyositis patients with anti-TIF1 antibodies: A case based comprehensive review. Autoimmun Rev. 2023;22(12):103464. doi:10.1016/j.autrev.2023.103464
12. Pinal-Fernandez I, Ferrer-Fabregas B, Trallero-Araguas E, et al. Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis. Rheumatology (Oxford). 2018;57(2):388-396. doi:10.1093/rheumatology/kex413
13. Casciola-Rosen L, Nagaraju K, Plotz P, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med. 2005;201(4):591-601. doi:10.1084/jem.20041367
14. Casciola-Rosen L, Mammen AL. Myositis autoantibodies. Curr Opin Rheumatol. 2012;24(6):602-608. doi:10.1097/BOR.0b013e328358bd85
15. Selva-O'Callaghan A, Grau JM, Gámez-Cenzano C, et al. Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis. Am J Med. 2010;123(6):558-562. doi:10.1016/j.amjmed.2009.11.012
16. Oldroyd AGS, Callen JP, Chinoy H, et al. International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative. Nat Rev Rheumatol. 2023;19(12):805-817. doi:10.1038/s41584-023-01045-w
17. Oldroyd AGS, Allard AB, Callen JP, et al. A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. Rheumatology (Oxford). 2021;60(6):2615-2628. doi:10.1093/rheumatology/keab166
18. Trallero-Araguás E, Gil-Vila A, Martínez-Gómez X, et al. Cancer screening in idiopathic inflammatory myopathies: Ten years experience from a single center. Semin Arthritis Rheum. 2022;53:151940. doi:10.1016/j.semarthrit.2021.12.008
19. Liu S, Zhang Z, Yan S, et al. Risk, risk factors, and screening of malignancies in dermatomyositis: current status and future perspectives. Front Oncol. 2025;15:1503140. Published 2025 Jun 4. doi:10.3389/fonc.2025.1503140
20. Oldroyd A, Sergeant JC, New P, et al. The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis. Rheumatology (Oxford). 2019;58(4):650-655. doi:10.1093/rheumatology/key357
21. Tiniakou E, Mammen AL. Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review. Clin Rev Allergy Immunol. 2017;52(1):20-33. doi:10.1007/s12016-015-8511-x
22. Yerolatsite M, Kekkou E, Torounidou N, Gerolymatou N, Zarkavelis G, Voulgari PV. Cancer-associated dermatomyositis: A scoping review of the literature. Autoimmun Rev. Published online July 6, 2026. doi:10.1016/j.autrev.2026.104136
23. Khanna U, Galimberti F, Li Y, Fernandez AP. Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening?. Ann Transl Med. 2021;9(5):432. doi:10.21037/atm-20-5215
24. Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, Milisenda JC, Grau-Junyent JM, Mammen AL. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018;17(9):816-828. doi:10.1016/S1474-4422(18)30254-0
25. Qiang JK, Kim WB, Baibergenova A, Alhusayen R. Risk of Malignancy in Dermatomyositis and Polymyositis. J Cutan Med Surg. 2017;21(2):131-136. doi:10.1177/1203475416665601
26. Mariampillai K, Granger B, Amelin D, et al. Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies. JAMA Neurol. 2018;75(12):1528-1537. doi:10.1001/jamaneurol.2018.2598
27. Lilleker JB, Vencovsky J, Wang G, et al. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis. 2018;77(1):30-39. doi:10.1136/annrheumdis-2017-211868
28. Lu X, Yang H, Shu X, et al. Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis. PLoS One. 2014;9(4):e94128. Published 2014 Apr 8. doi:10.1371/journal.pone.0094128
29. Lega JC, Reynaud Q, Belot A, Fabien N, Durieu I, Cottin V. Idiopathic inflammatory myopathies and the lung. Eur Respir Rev. 2015;24(136):216-238. doi:10.1183/16000617.00002015
30. Dani L, Holmqvist M, Martínez MA, et al. Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study. Clin Exp Rheumatol. 2020;38(1):67-73.
31. Best M, Molinari N, Chasset F, Vincent T, Cordel N, Bessis D. Use of Anti-transcriptional Intermediary Factor-1 Gamma Autoantibody in Identifying Adult Dermatomyositis Patients with Cancer: A Systematic Review and Meta-analysis. Acta Derm Venereol. 2019;99(3):256-262. doi:10.2340/00015555-3091
32. Selva-O'Callaghan A, Ros J, Gil-Vila A, Vila-Pijoan G, Trallero-Araguás E, Pinal-Fernandez I. Malignancy and myositis, from molecular mimicry to tumor infiltrating lymphocytes. Neuromuscul Disord. 2019;29(11):819-825. doi:10.1016/j.nmd.2019.09.014
33. Li X, Tan H. Value of 18F-FDG PET/CT in the detection of occult malignancy in patients with dermatomyositis. Heliyon. 2020;6(4):e03707. Published 2020 Apr 3. doi:10.1016/j.heliyon.2020.e03707
34. Yildiz H, D'abadie P, Gheysens O. The Role of Quantitative and Semi-quantitative [18F]FDG-PET/CT Indices for Evaluating Disease Activity and Management of Patients With Dermatomyositis and Polymyositis. Front Med (Lausanne). 2022;9:883727. Published 2022 Apr 15. doi:10.3389/fmed.2022.883727
35. Selva-O'Callaghan A, Martinez-Gómez X, Trallero-Araguás E, Pinal-Fernández I. The diagnostic work-up of cancer-associated myositis. Curr Opin Rheumatol. 2018;30(6):630-636. doi:10.1097/BOR.0000000000000535
36. Tang IYK, Chan SCW, Li PH, et al. Validation of the International Myositis Assessment and Clinical Studies Group guideline on cancer risk stratification. Rheumatology (Oxford). 2025;64(4):2106-2114. doi:10.1093/rheumatology/keae504
37. Silva I, Dayanan J, Nigro A, et al. International Myositis Assessment and Clinical Studies Guidelines for Risk-Based Cancer Screening: An External Validation in Patients With Dermatomyositis Seen at a Metropolitan Academic Center. ACR Open Rheumatol. 2026;8(7):e90101. doi:10.1002/acr2.90101
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Paulina Patrycja Turzyńska, Marcjanna Maria Liedtke, Weronika Martynowska , Mateusz Martynowski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 81
Number of citations: 0
